Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990602 | 1.00 | GLA (0.38) | GLAEPHX2LMNAMAOBNAAA | |
| SCHEMBL19990678 | 0.74 | TGM2 (0.33) | EPHX2LMNA | |
| SCHEMBL22368477 | 0.74 | TGM2 (0.33) | EPHX2LMNA | |
| SCHEMBL20009183 | 0.73 | BACE1 (0.36) | EPHX2CTSL | |
| SCHEMBL3662286 | 0.71 | DPP8 (0.45) | EPHX2 | |
| SCHEMBL20009197 | 0.71 | PARP1 (0.39) | GLAKMT2A | |
| SCHEMBL28303293 | 0.69 | HTR1A (0.35) | EPHX2MAOBHTR1ASLC6A2SLC6A4 | |
| SCHEMBL28304424 | 0.69 | L3MBTL1 (0.40) | GLAEPHX2CTSLKMT2A | |
| SCHEMBL21293006 | 0.68 | ALDH1A1 (0.35) | GLAEPHX2MAOB | |
| SCHEMBL17232240 | 0.68 | ALDH1A1 (0.35) | GLAEPHX2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-B1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | NOVARTIS AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |